We are pleased to share an article by Przemysław Mazurek, CEO of NanoGroup, published in Forbes Polska magazine entitled: “Quo Vadis for Biotechnology? The Companies ‘Just Want to Extend Human Life” .
The article introduces readers to why biotechnology is becoming a key field of science and business, and how it is changing our perception of medicine. Przemysław Mazurek notes that although biotechnological technologies are less spectacular than AI or blockchain, their impact on our lives can be much deeper.
In Poland, over 4 million people suffer from chronic kidney disease, many of whom require dialysis or transplantation. Meanwhile, the number of available organs is limited – in the article, the CEO of NanoGroup S.A. indicates that one of the goals of modern biotechnology is to find solutions that will increase the availability of organs for transplantation and extend their life outside the body. Such innovations can significantly improve the quality and length of life of patients.
NanoGroup, as part of the dynamically developing biotechnology sector, is actively working on solutions that can contribute to the development of transplantology and other fields of medicine. Mazurek points out that Polish biotechnology is also gaining importance in the global context – it is increasingly becoming the subject of interest from foreign investors.
We invite you to read the entire article, where you will find more details about the current challenges and opportunities facing biotechnology: